Susquehanna International Group’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.67M | Sell |
127,664
-10,371
| -8% | -$298K | ﹤0.01% | 1614 |
|
|
2025
Q1 | $4.63M | Buy |
138,035
+87,784
| +175% | +$2.94M | ﹤0.01% | 1296 |
|
|
2024
Q4 | $2.57M | Buy |
50,251
+436
| +0.9% | +$22.3K | ﹤0.01% | 1680 |
|
|
2024
Q3 | $2.55M | Buy |
49,815
+13,955
| +39% | +$713K | ﹤0.01% | 1649 |
|
|
2024
Q2 | $1.61M | Sell |
35,860
-14,422
| -29% | -$646K | ﹤0.01% | 1990 |
|
|
2024
Q1 | $2.35M | Buy |
50,282
+26,600
| +112% | +$1.25M | ﹤0.01% | 1634 |
|
|
2023
Q4 | $843K | Sell |
23,682
-51,461
| -68% | -$1.83M | ﹤0.01% | 3096 |
|
|
2023
Q3 | $2.23M | Buy |
75,143
+47,716
| +174% | +$1.42M | ﹤0.01% | 1734 |
|
|
2023
Q2 | $494K | Sell |
27,427
-34,560
| -56% | -$623K | ﹤0.01% | 3639 |
|
|
2023
Q1 | $996K | Buy |
61,987
+51,752
| +506% | +$831K | ﹤0.01% | 2901 |
|
|
2022
Q4 | $187K | Sell |
10,235
-26,062
| -72% | -$477K | ﹤0.01% | 4540 |
|
|
2022
Q3 | $713K | Buy |
36,297
+23,628
| +187% | +$464K | ﹤0.01% | 3012 |
|
|
2022
Q2 | $236K | Sell |
12,669
-65,238
| -84% | -$1.22M | ﹤0.01% | 4330 |
|
|
2022
Q1 | $1.71M | Buy |
77,907
+30,991
| +66% | +$680K | ﹤0.01% | 2185 |
|
|
2021
Q4 | $1.33M | Buy |
46,916
+31,869
| +212% | +$905K | ﹤0.01% | 2457 |
|
|
2021
Q3 | $317K | Buy |
+15,047
| New | +$317K | ﹤0.01% | 4242 |
|